Showing results (81-90 of 125) with videos related to
Sort By:
Pageof 13
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthBrion W Murray, Chuangxing Guo, Joseph Piraino, et al.The New England Journal of Medicine|December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12CRona Yaeger, Jared Weiss, Meredith S Pelster, et al.Cancer Discovery|August 6, 2021
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLCKwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.Molecular Cancer Therapeutics|July 14, 2011
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activityJing Yuan, Pramod P Mehta, Min-Jean Yin, et al.Cancer Discovery|July 8, 2024
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic CancerAnupriya Singhal, Hannah C Styers, Jonathan Rub, et al.Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.The New England Journal of Medicine|October 29, 2010
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumorJames E Butrynski, David R D'Adamo, Jason L Hornick, et al.Pageof 13